Now, scientists are saying they’ve got one of the most definitive leads yet for a bacterial culprit behind Alzheimer’s, and it comes from a somewhat unexpected quarter: gum disease.
In a new paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers report the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer’s patients.
It’s not the first time the two factors have been linked, but the researchers went further.
In separate experiments with mice, oral infection with the pathogen led to brain colonisation by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer’s.
The research team, which is coordinated by pharma startup Cortexyme that was co-founded by first author Stephen Dominy, isn’t claiming to have discovered definitive evidence of Alzheimer’s causation. Yet.
But it’s clear they think we’ve got a strong line of investigation here.
“Infectious agents have been implicated in the development and progression of Alzheimer’s disease before, but the evidence of causation hasn’t been convincing,” Dominy says.
“Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer’s pathogenesis.”
In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer’s patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin.
But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer’s.
That’s important, because while P. gingivalis and the disease have been linked before, it’s never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care.
The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer’s could be a smoking gun – suggesting they might have developed the condition if they had lived longer.
“Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline,” the authors write in their paper.
Further, a compound formulated by the company called COR388, which is already going through clinical trials with Alzheimer’s patients, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation.
We’ll have to wait and see what future research will uncover about this link – and the potential benefits of COR388 – but the research community is cautiously optimistic.
“Drugs targeting the bacteria’s toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it’s important that we test as many approaches as possible to tackle diseases like Alzheimer’s,” chief scientific officer David Reynolds from Alzheimer’s Research commented in a statement.
“We will have to see the outcome of this ongoing trial before we know more about its potential as a treatment for Alzheimer’s.”